May Emerging Medical Technologies Report

•Cost effective, non-invasive point of care diagnostics that use bio-sensor chips to provide direct, digital, state of the art sensitivity (fM - pM) and selectivity through proprietary semiconductor processing of CNT FETs and may be used to diagnose a variety of diseases and related health risks
•A second-generation biomimetic coating comprised of 2 protein components (FN and SDF-1α) which may be applied to cardiovascular prostheses in order to help avoid tissue rejection and subsequent device failure
•Molecular diagnostics technologies that perform directed analyses of cell-free DNA in blood and are used to provide safe, highly accurate, and affordable prenatal tests for maternal and fetal health
•A tubular valve implanted through the mouth during an ambulatory procedure for the treatment of gastroesophageal reflux disease (GERD), although future applications for the technology include obesity and irritable bowel syndrome
•Highly compact intensity-modulated proton therapy medical system powered by a dielectric-wall accelerator and intended for use in oncology patients; features a revolutionary design with a substantially smaller structure and greater flexibility than other accelerators
•A patented electro-chemical technology for coating teeth with a high concentration of target materials that last for long periods of time, and include the following applications: (1) Fluoritray, a non-invasive, painless tooth fluoridation, producing a thick protective Fluoroapatite layer lasting for more than one year, reducing sensitivity and significantly improving resistance to bacteria and the acidic mouth environment; and (2) UltraWyte, for superior tooth whitening
•A novel, disposable device used for intra-abdominal pressure monitoring in patients that are receiving gastric feeding, require safe monitoring of gastric residual volume, or are being screened for intra-abdominal hypertension
•An FDA-cleared dual-balloon catheter for urinary drainage that is designed to reduce adverse events resulting from Foley urinary catheterization, including the occurrence of Catheter Associated Urinary Tract Infections (CAUTI), sepsis, and bladder cancer in long-term users
•SideView Mono trocar for single access laparoscopic surgery
•Patent-pending T-Loc(TM) Technology, used for the treatment of fractures and injuries to the shoulder joint and allowing precise, reproducible surgeon-controlled tensioning and low-profile, knotless fixation
•Non-invasive system to detect and alert users of sleep-time hypoglycemia for the monitoring of type 1 diabetes
•Research and development of innovative biotechnologies
•Novel spherical nucleic acid (SNA) constructs exhibiting biocompatibility and versatility as intended therapeutics to treat heart disease, cancer, skin conditions and bacterial infection
•Therapeutics intended to treat diabetes, diabetic complications, and kidney disease through the inhibition of blood vessel growth, preventing hyperglycemia-induced damage to proteins and tissues
•Cellular Regeneration Technology (CRT) utilizing cell interaction and a functional polymer scaffolding to provide a single-surgery treatment for damaged articular cartilage in the knee
•Innovative oral therapy to treat rheumatoid arthritis and inhibit disease progression
•Small molecule drug candidates directed at ion channel targets to repurpose existing therapies for atrial fibrillation
•First-in-class oncology therapeutics to treat female and male cancers utilizing membrane-disrupting peptides to target cancer cells without harming healthy tissue
•Minimally invasive ultrasound device that allows for rapid evaluation of fallopian tubes to assess fertility at point of care
•Novel, implantable cardiovascular device for the treatment of a prevalent cardiovascular condition
•Blended active glycolic acid used in cosmetic and beauty products
•Sustainable chemicals using unconstrained metabolism technology for reaction flexibility
•Novel therapeutic intended to treat dry age-related macular degeneration and prevent blindness
•Novel DNA-based immunotherapies to treat HIV
•Cell-based nuclear receptor reporter assay technology used in drug development that allows for the storage and preservation of cells for later use
•Innovative platform that optimizes DNA to produce in vivo therapeutics with multiple indications
•Budesonide-based therapy for the treatment of eosinophilic esophagitis
•Catheter-based medical technologies for the treatment of cerebral aneurysm and other cardiovascular disease
•Optical measurement instruments using back-scattering interfermetry to detect molecular interaction assays and assist in developing drug applications
•Novel formulations of existing pharmaceuticals to expand applicable patient populations and therapeutic uses
•Technology that enables Innovative reformulation of previously approved therapeutics to expand indications or improve safety
•Targeted UV phototherapy device to treat dermatological diseases including eczema, psoriasis and vitiligo
•Novel therapeutic to treat age-related macular degeneration and prevent blindness
•Affordable analytical instruments, biomanufacturing systems, and consumable labware products for biological research and drug discovery
•Formulations for lymphatic delivery of highly lipophilic pharmaceuticals
•Novel MRI scanner to diagnose disease and provide real time guidance of thermal energy procedures such as lesion biopsies and tumor treatments
•Reformulation of existing pharmaceuticals to provide more targeted results, lessen the risk of side effects and reduce patient costs; lead product is an oral form of an existing IV-only cancer drug
•Innovative combination drug therapies to treat overactive bladder and urinary incontinence
•Spiral Laminar Flow (SLF) prosthetic grafts are used to reproduce the body's natural blood flow patterns and treat cardiovascular disease
•SMaRT RNA technology intended to treat a broad spectrum of diseases including HIV, hemophilia and dyslipidemia
•Novel, first-in-class therapeutic utilizing beloranib to treat severe obesity